Group 1 - Company held its 13th meeting of the 11th board of directors on October 15, 2025, in Shanghai, discussing strategic planning documents [1] - For the year 2024, the revenue composition of the company is as follows: pharmaceutical manufacturing accounts for 54.76%, trading business for 17.33%, textile industry for 14.83%, and other businesses for 13.08% [1] - The current market capitalization of the company is 8.1 billion yuan [2]

Group 1 - The Shanghai Stock Exchange issued a decision to criticize Shanghai Yilian Industrial Group Co., Ltd. and its responsible persons for violations related to information disclosure and corporate governance [1][3] - The company failed to report restricted funds of 1 billion yuan in its 2023 semi-annual report and incorrectly reported the same amount as cash and cash equivalents [1][2] - The company’s internal controls were found to have significant deficiencies, as large deposits were pledged without proper approval and payment of 1 billion yuan was made to suppliers without following the necessary procedures [2][3] Group 2 - The responsible parties, including the former chairman and the former general manager, were found to have not fulfilled their duties, leading to violations of various regulations [3][5] - The disciplinary action taken includes a public reprimand for the company and the responsible individuals, which will be recorded in the integrity database of the securities and futures market [5] - For the first half of 2024, the revenue composition of *ST Yilian was reported as follows: 89.12% from color printing and packaging, 4.87% from real estate, 4.7% from trade, and 1.3% from other main businesses [5]